TW200816926A - A black tea extract and uses thereof - Google Patents
A black tea extract and uses thereof Download PDFInfo
- Publication number
- TW200816926A TW200816926A TW95136486A TW95136486A TW200816926A TW 200816926 A TW200816926 A TW 200816926A TW 95136486 A TW95136486 A TW 95136486A TW 95136486 A TW95136486 A TW 95136486A TW 200816926 A TW200816926 A TW 200816926A
- Authority
- TW
- Taiwan
- Prior art keywords
- black tea
- extract
- ammonia water
- ammonia
- pharmaceutical composition
- Prior art date
Links
- 244000269722 Thea sinensis Species 0.000 title claims abstract description 106
- 235000020279 black tea Nutrition 0.000 title claims abstract description 99
- 235000006468 Thea sinensis Nutrition 0.000 title claims abstract description 98
- 239000000284 extract Substances 0.000 title claims abstract description 86
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims abstract description 79
- 201000011510 cancer Diseases 0.000 claims abstract description 28
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 21
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- 206010042496 Sunburn Diseases 0.000 claims abstract description 9
- 206010027476 Metastases Diseases 0.000 claims abstract description 7
- 230000009401 metastasis Effects 0.000 claims abstract description 7
- 239000007921 spray Substances 0.000 claims abstract description 7
- 238000002347 injection Methods 0.000 claims abstract description 6
- 239000007924 injection Substances 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 64
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 53
- 239000006286 aqueous extract Substances 0.000 claims description 30
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 18
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 206010038038 rectal cancer Diseases 0.000 claims description 16
- 201000001275 rectum cancer Diseases 0.000 claims description 16
- 239000006071 cream Substances 0.000 claims description 14
- 229910021529 ammonia Inorganic materials 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 230000012010 growth Effects 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 150000003254 radicals Chemical class 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000002244 precipitate Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 238000004448 titration Methods 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000037380 skin damage Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 241000124033 Salix Species 0.000 claims 1
- 240000008866 Ziziphus nummularia Species 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 abstract description 4
- 239000000908 ammonium hydroxide Substances 0.000 abstract 3
- 230000004614 tumor growth Effects 0.000 abstract 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 235000013616 tea Nutrition 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 230000002000 scavenging effect Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 235000014620 theaflavin Nutrition 0.000 description 4
- 235000008118 thearubigins Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 235000012984 Aspalathus linearis Nutrition 0.000 description 2
- 240000006914 Aspalathus linearis Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 2
- 229940026509 theaflavin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- 238000007808 Cell invasion assay Methods 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 238000007807 Matrigel invasion assay Methods 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010866 blackwater Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VGVYRHYDNGFIGF-UHFFFAOYSA-N fumarin Chemical compound OC=1OC2=CC=CC=C2C(=O)C=1C(CC(=O)C)C1=CC=CO1 VGVYRHYDNGFIGF-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine acetate Natural products C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 1
- 229960003351 prussian blue Drugs 0.000 description 1
- 239000013225 prussian blue Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- -1 whitening Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
200816926 九、發明說明: 【發明所屬之技術領域】 本發明係有關於一種紅茶萃取物,特別是一種紅茶的 氣水卒取物’其具有防止皮膚囉傷、製備抑制惡性腫瘤生 長及抑制癌細胞轉移的功效。 【先前技術】 紅茶為一種普遍受歡迎的飲料,在製作紅茶的過程 中,茶葉中的多酚會經過多酚氧化酶激化氧化聚合,導致 雙黃烷醇(bisflavanol)、茶黃素(theaflavin)、茶紅素 (thearubigin)及其他寡聚物(oligomer)的形成。(Wei等人,200816926 IX. Description of the invention: [Technical field of the invention] The present invention relates to a black tea extract, in particular to a gas-water stroke of black tea, which has the functions of preventing skin bruising, preparing for inhibiting growth of malignant tumors, and inhibiting cancer cells. The effect of the transfer. [Prior Art] Black tea is a popular beverage. During the process of making black tea, the polyphenols in the tea will undergo oxidative polymerization by polyphenol oxidase, resulting in bisflavanol and theaflavin. , the formation of thearubigin and other oligomers (oligomers). (Wei et al,
Scavenging of hydrogen peroxide and inhibition of ultraviolet light-induced oxidative DBA damage by aqueous estracts from green and black teas. Free Radio Biol Med. 1999, Jun; 26(11-12): 1437_35; Lambert 等人,Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr. 2005 Jan; 81(1 Suppl): 284S-291S,Review)。在紅茶的水萃取物中,;μ2〇/〇的固體 為提供紅茶色澤與味道的茶黃素,而絕大部分紅茶的水萃 取物為茶紅素,其具有較大範圍的分子量但性質特徵尚未 鑑定完成。 過去研究發現紅茶萃取物具有抗氧化,抗致癌性及抗 突變的作用(Lambert等人,2005),而一般假設這些作用 是來自於紅茶内的多酚,如茶黃素與茶紅素。在茶葉的發 酵過程’茶黃素與茶紅素為氧化與冷凝反應的產物。近年 5 200816926 來,發展了數種由紅茶萃取生物活性物質的方法,在最初 萃取步驟最常用的溶劑為沸水與乙醇,接著再經過一系列 有機溶劑取得多酚或茶色素。2002年Hung等人報導紅茶 色素可經由氨水萃取及後續有機溶劑取得,並進一步研究 發現該等色素對於消化道之磁共振圖像(magnetic resonance imaging,騰I)具有改善之效果,以及對於聯氨 (Hydrazine)引起的肝臟損傷具有保護功效。而Hung等人經 鑑疋認為该萃取得之紅茶色素是黑色素(meianin) (Hung等 人’ Gastrointestinal enhancement of MRI with melaninScavenging of hydrogen peroxide and inhibition of ultraviolet light-induced oxidative DBA damage by aqueous estracts from green and black teas. Free Radio Biol Med. 1999, Jun; 26(11-12): 1437_35; Lambert et al., Inhibition of carcinogenesis by polyphenols : evidence from laboratory investigations. Am J Clin Nutr. 2005 Jan; 81(1 Suppl): 284S-291S, Review). In the aqueous extract of black tea, the solid of μ2〇/〇 is the theaflavin which provides the color and taste of black tea, and the water extract of most black tea is thearubigin, which has a wide range of molecular weight but characteristic of nature. Not yet certified. Previous studies have found that black tea extracts have anti-oxidant, anti-carcinogenic and anti-mutation effects (Lambert et al., 2005), and it is generally assumed that these effects are derived from polyphenols in black tea, such as theaflavins and thearubigins. In the fermentation process of tea leaves, theaflavins and thearubigin are products of oxidation and condensation reactions. In recent years 5 200816926, several methods for extracting biologically active substances from black tea have been developed. The most commonly used solvents in the initial extraction step are boiling water and ethanol, followed by a series of organic solvents to obtain polyphenols or tea pigments. In 2002, Hung et al. reported that black tea pigment can be obtained by ammonia water extraction and subsequent organic solvents, and further studies have found that these pigments have an improved effect on magnetic resonance imaging (Teng I) and hydrazine. Liver damage caused by (Hydrazine) has protective effects. Hung et al. believe that the extracted black tea pigment is meianin (Hung et al.' Gastrointestinal enhancement of MRI with melanin
derived from tea leaves (Thea sinesis Linn.). JDrawn from tea leaves (Thea sinesis Linn.). J
Ethnopharmacol. 2002 Jan; 79(1): 75_9; Hung 等人,Ethnopharmacol. 2002 Jan; 79(1): 75_9; Hung et al.
Protection of tea melanin on hydrazine-induced liver injury.Protection of tea melanin on hydrazine-induced liver injury.
Life Sci· 2003 Jan 17; 72(9):1061-71)。 前述研究及報告中均未曾報導具有抑制惡性腫瘤生長 及抑制癌細胞轉移的功效的紅茶萃取物。 【發明内容】 、本發日歸m纟X茶萃取物,其細氨水萃麵得,其特徵 ^紅錢水萃取物在電喷灑游離質譜分析(ESI_MS)條件為負極 電=灑游離狀態,掃描範圍在15G至·的f 電荷比内,及注 身憎浦、LC幫浦的流速均為2〇微升/分鐘時,產生質量/電荷比 分別為約2〇4·5、226 3與368 6的三個特科值。 於防止皮膚曬 智另一方面,本發明提供該紅茶萃取物用 ^之用途,及其用於防止皮膚曬傷之組合物 200816926 及 其用===::種清除自由基之用途 途 又—方面,本發明提供該紅茶萃取物用於抗氧化之用 及其用於抗氧化之組合物。Life Sci· 2003 Jan 17; 72(9): 1061-71). Black tea extracts having the effects of inhibiting the growth of malignant tumors and inhibiting the metastasis of cancer cells have not been reported in the foregoing studies and reports. [Summary of the Invention] The present invention is a m纟X tea extract obtained by extracting fine ammonia water, and the characteristics of the red money water extract are determined by electrospray ionization mass spectrometry (ESI_MS) as negative electrode=sprinkle free state. The scan range is from 15G to · f charge ratio, and when the flow rate of the injection pump and the LC pump are 2 〇 microliters/min, the mass/charge ratio is about 2〇4·5, 226 3 and 368 respectively. 6 of the three special values. On the other hand, the present invention provides the use of the black tea extract, and the composition thereof for preventing sunburn, 200816926, and the use of the ===:: scavenging free radicals. In one aspect, the present invention provides the black tea extract for use in antioxidants and compositions thereof for use in antioxidants.
έ再又另一方面,本發明提供該紅茶萃取物用於抑制癌 、、田胞轉移之用途,及其躲抑制癌細胞轉移之醫藥組成物。 【實施方式】 本發明係提供一種紅茶萃取物,其係由氨水萃取而得,其特徵為 忒紅余氨水萃取物在電喷灑游離質譜分析(ESI_MS)條件為負極電 • 噴灑游離狀態,掃描範圍在15〇至2500的質量/電荷比内,及注射 ▲ 絮浦、LC幫浦的流速均為20微升/分鐘時,產生質量/電荷比分 、 別為約204.5、226·3與368.6的三個特定峰值。 根據本發明的一實施例,該紅茶氨水萃取物之製備方 法包括將紅茶茶葉浸泡於Μ0%氨水並過濾以取得過濾 ’夜,✓辰、纟侣该過濾液並進行酸滴定(pH值在範圍内),接 著將滴定所得的溶液離心,去上層液以取得沉澱物。接著 將沉澱物置於-VC至-8(TC使其結凍並於隨後解凍沉澱物 後’去除上層液後以取付紅余氨水萃取物。 7 200816926 根據本發明的另一實施例, 上層液後’還可再進行第二次萃取,===解來去除 於M0%氨水後進行濃縮,再進行酸滴^t 物溶 圍内),之後置於至鲁 Μ I值在1-4範 解珠後,去除上層液。最後,對結4 °再將沉殿物 得紅茶氨水萃取物。 w ^物進仃冷凍乾燥以取 在本發明之具體實施例中,Further, in another aspect, the present invention provides the use of the black tea extract for inhibiting cancer, cell metastasis, and a pharmaceutical composition for preventing metastasis of cancer cells. [Embodiment] The present invention provides a black tea extract obtained by extracting ammonia water, which is characterized in that the eosin residual ammonia aqueous extract is subjected to electrospray ionization mass spectrometry (ESI_MS) under the condition of a negative electric current, a spray free state, and a scan. In the mass/charge ratio ranging from 15〇 to 2500, and when the flow rate of the injection ▲ floc and LC pump is 20 μl/min, the mass/charge ratio is generated, which is about 204.5, 226·3 and 368.6. Specific peaks. According to an embodiment of the present invention, the method for preparing the black tea ammonia water extract comprises: immersing black tea leaves in Μ0% ammonia water and filtering to obtain filtered 'night, ✓ chen, monk the filtrate and performing acid titration (pH is in the range) Inside), the solution obtained by titration is then centrifuged, and the supernatant is removed to obtain a precipitate. The precipitate is then placed at -VC to -8 (TC is allowed to freeze and after the thawing of the precipitate is subsequently removed) to remove the red residue aqueous ammonia extract. 7 200816926 According to another embodiment of the invention, after the supernatant 'You can also carry out the second extraction, === solution to remove the M0% ammonia water and then concentrate it, then carry out the acid drop ^t substance in the solution), and then put it to the Luyi I value in the 1-4 range After the beads, remove the supernatant. Finally, the knot will be 4 ° and then the sink will be a black tea ammonia extract. W ^ 仃 仃 freeze drying to take in a specific embodiment of the invention,
V 了第-次與第二次萃取步驟 χ據貝“要’在進行 取,最後’再對㈣物進行冷;驟t續進行萃 取物。因此,本發明的萃取步二:#紅茶的氨水萃 ㈣士 a 口 乂驟亚不限於特定的萃取次數。 根據本發明上述的萃取方法 物,依照料分析,4^2料水卒取 離狀態’掃描範圍介於150至25〇;=^^ !幫二、LC幫浦的流速均為2〇微升/分鐘二生二 204'5^ 2263 # 368·6 m 的峰值分麵胁分析其他紅茶萃 =物的以衫㈣,本發明紅錢水萃取物確實具有獨 4寸的物理特性’與習知技藝中所述紅茶氨水萃取物的主要 活性成分黑色素並不相同。本發明所提供之紅茶氨水萃取 物確屬新穎。 另外’經由分光光譜儀(spectrophotometer)分析本發明 紅茶氨水萃取物之吸光值,發現本發明紅茶氨水萃取物能 吸收波長範圍在200_400 nm的光線,其中涵蓋了紫外光的 波長,證實本發明紅茶氨水萃取物具有吸收紫外光之功 8 200816926 效,可用於防曬。 除此之外’在清除自由基與還原力的試驗中也證實了 本發明紅茶氨水萃取物具有清除自由基的能力與還原力。 根據本發明,本發明提供一種防止皮膚曬傷之用途及 組成物,其包含係以本發明紅茶氨水萃取物為活性成分, /、酉學上或化妝品可接受之载劑混合製成。由於多數的皮 膚曬傷乃是長期受陽光中的紫外線曝曬所致,而本發明紅 鲁茶氨水萃取物能有效吸收了陽光中的紫外光,可有效防止 皮膚曬傷。亦可作為化粧品組成物或醫藥組成物等。 根據本發明的一較佳實施例,製備該防止皮膚曬傷之 組成物的方法係以本發明紅茶氨水萃取物為活性成分,與 :亥醫學上或化妝品可接受之载劑,包括水、乳液、乳霜、 ^貧或其組合所混合製成。且由於該組錢用途在於防止 =曬傷’因此組成物可以製作成不同形式,包括喷劑、 礼《、乳液、孔霜或面膜方式,以方便供需要防止 • ^的使用者使用’錢用頻率或劑量可根據使用者實際的 ‘ 需求自行調整。 、 、口 &本發明防止皮膚曬傷之組成物,可視需要另包含化妝 :吊用之佐劑或添加劑,例如乳化劑、增黏劑、界面活性 ^螯合劑、抗菌劑、防腐劑、著色劑、香料等。熟習該 ,技術者可依自身之專業知識、經驗以及需求由習㈣劑 ^添加劑中選擇適合的種類並決定其添加量。再者,本發 明防止皮膚曬傷之組成物亦可另包含其他活性劑,為皮膚 提供額外之益處。常見之活性劑包括,但不限於,滋潤劑二 9 200816926 保濕劑、抗氧化劑、防曬劑、抗老化劑、美白、及 質劑。 月 月 並提供—種清除自由基之料及醫藥組成物。 ^中=樂組成物係將本發明紅茶氨水萃取物做為活性成 刀:契醫學上可接受之賦形劑混合而成。該醫學上可 之賦形劑包括結合劑、填充劑及穩定劑。 又 本發明亦提供一種抗氧化之用途及醫筚 ==係將广紅茶氨水萃取物做為活性成;中 契商子上可接受之賦形劑混合Μ。該醫學 形劑包括結合劑、填錢及穩定劑。 接又之賦 本!明也提供一種抑制惡性腫瘤生長之用途及醫藥組 活性成分,與醫學上可接受之_劑混 可接受之賦形劑包括結合劑、填充劑及穩定劑。以酉子 癌。 、反^届、基底細胞 本餐明另提供一種抑制癌細胞轉移之用途 =本發明的-較佳實施例,本發明紅茶氨 '、可㈣直腸癌細胞轉移’且特別係針 的移行能力與侵襲能力。 絲癌細胞 =树_實_,本發”藥組成物係 、、、木乳水卒取物為活性齡,㈣學上可衫w形劑混 200816926 合製成,其中該醫學上可接受之賦形劑包括結合劑、填充 劑及穩定劑。同樣的,該醫藥組成物可製作成滴液、藥水、 藥粉、藥錠、膠囊、喷劑或貼片的不同形式以方便使用者 的服用,但本發明醫藥組成物並不限於上述幾種形式,任 何熟知製藥的人士都可清楚瞭解上述組成物的其他給藥方 式都在本發明的範圍。本發明醫藥組成物可依據熟習該項 技術者可依自身之專業知識、經驗以及需求使用適量之本 發明組合物。可依其症狀輕重自行決定施用頻率及劑量, 或依醫師等專業人士之指示或建議施用。 本發明以下列特定但非限制的實例作更詳盡的描述。 實施例1 :紅茶氨水萃取物的製備及鑑定 1.1氨水萃取物的製備 秤取紅茶葉於熱水中煮沸10分鐘,撈起煮過之紅茶葉 體積以1 : 10浸泡於2%氨水中室溫攪拌整夜。次日進行過 濾,過濾液於真空減壓濃縮機以50°C條件下進行處理,使 總體積剩為濃縮前的1/2。得到的濃縮液以5N鹽酸進行滴 定至ρΗ2·5,並在室溫下靜置4小時,再以10,000g離心 10分鐘,去上層液將沈澱物置於-20°C冰箱使其結凍。解凍 後去除上層液,將沈澱物溶於酸滴定前體積之2%氨水中, 進行第二次萃取,於5CTC以具有每分鐘90轉之轉速的真 空濃縮機處理約剩總體積的1/2至1/3。再進行酸滴定至 π 200816926 ρΗ2·5,且在室溫靜置4小時以上,之後移入-20°C冰箱中 使其完全結珠。再將沈殿物解束後,去除上層液。沈殿物 加入第二次酸滴定前體積的2%氨水,使其溶解。再進行濃 縮處理,重複第一、二次萃取的方式,最後將沈澱物置於 _80°C 下 1 小時,以冷凍乾燥機(dura_DRY; FTS Systems, Inc· San Francisco, USA)進行乾燥。所得的乾燥物即為本發 明紅茶氨水萃取物。 1·2電喷灑游離質譜法(ESI-MS) 將如前述實施例1.1所得之乾燥紅茶氨水萃取物與其 他方式之萃取物進行電喷灑游離質譜儀分析之比較,比較 之萃取物包括依習知方法製得之水萃取物、醋酸乙酯萃取 物與70%乙醇萃取物。其中氨水萃取物與水萃取物以1〇毫 莫爾(mM)的氨水溶液重新溶解為濃度i微克/微升(μ§/μ1) 的溶液,而另二種萃取物維持流體狀態而不做進一步處理。 土以250 μΐ的注射筒連續注入樣本,使用τ型閥連接注 射,浦與LC幫浦的管線將分析物送入電喷灑游離源,上 述土4浦的/现速均為20 μΐ/min(分鐘)。在負極電噴灑游離狀 態下’以150至25〇〇的質量/電荷比範圍完全掃描每一樣 本數分鐘以取得平均光譜。 如第1圖⑻所示’在本發明紅茶氨水萃取物質譜圖 現質量/電荷比分別為朗、226 3與368 6的三個特定^ 值,在其他紅茶萃取物的質譜分析中,可發現水萃取 的質量/電荷比分別為⑽·8、336.6與_(第 12 200816926 酉夂乙酉^萃取物所呈現的質量/電荷比分別為348 8、44〇 6與 883.0(第i圖⑽,而乙醇萃取物所電別 ^侧、咖與衝($1_。依^上述質譜分析結 ^可有效分辨本發敝錢水觀倾水萃取物、 醋酸乙 酿萃取物及乙料取物分別為不同的物質。 除另有特別說明,以下實施例所使用的紅茶萃取物均 為依據本實施例所製得之本發明紅茶氨水萃取物。 實施例2:本發明紅茶氨水萃取物之紫外光吸收分析 2·ι小鼠抗UV試驗 將8·1〇週齡退父品種(ICR)小鼠(購自國科會動物中心) 以Avertin ( 15 ml/kg)麻醉後刮除背部的毛,如第2圖所 示般劃分為三個區域,分別塗抹水(區域b)、含丨%紅茶萃 取物以習之方法製成之乳霜(區域d)與不含萃取物之空白 乳霜(區域c)。依塗抹劑量(2 mg/cm2和2〇 mg/cm2)與照射 不同紫外線波長(紫外光A(UV_A) : 320至400 nm、UV_B : 290至320 nm、UV-C : 200至290 nm)將上述小氣分成6 組,每組至少2隻。除欲照射之部位外,小鼠的其餘部位V has the first-time and second extraction steps, according to the shell, "to be taken, and finally, to (4) the object is cooled; the extract is continued. Therefore, the extraction step 2 of the invention: #黑茶的氨水The extraction method is not limited to a specific extraction number. According to the above extraction method of the present invention, according to the material analysis, the 4^2 water-slipping state is scanned from 150 to 25 〇; =^^ The flow rate of the second and LC pumps is 2 〇 microliters per minute. The second generation is 204'5^ 2263 # 368·6 m The peak value of the face is analyzed. Other black tea extracts = the clothes of the shirt (four), the red money of the present invention The water extract does have a physical property of 4 inches, which is different from the main active ingredient melanin of the black tea ammonia water extract described in the prior art. The black tea ammonia water extract provided by the present invention is novel. Further 'via spectroscopic spectrometer Spectrophotometer analyzes the absorbance of the black tea ammonia water extract of the present invention, and finds that the black tea ammonia water extract of the present invention can absorb light having a wavelength range of 200-400 nm, which covers the wavelength of ultraviolet light, and confirms that the black tea ammonia water extract of the present invention has ultraviolet light absorption. It 8 200816926 effect, can be used for sun protection. In addition, in the test for scavenging free radicals and reducing power, it was also confirmed that the black tea ammonia aqueous extract of the present invention has the ability to scavenge free radicals and reducing power. According to the present invention, the present invention provides a The use and composition for preventing skin sunburn, which comprises the use of the black tea ammonia aqueous extract of the present invention as an active ingredient, /, a drop-off or a cosmetically acceptable carrier, because most skin sunburns are long-term exposures. The ultraviolet light exposure in the sunlight is caused, and the aqueous extract of the red tea of the present invention can effectively absorb the ultraviolet light in the sunlight, and can effectively prevent the skin from being sunburned. It can also be used as a cosmetic composition or a pharmaceutical composition, etc. According to the present invention In a preferred embodiment, the method for preparing the skin-inhibiting composition is the active ingredient of the black tea ammonia aqueous extract of the present invention, and the medical or cosmetically acceptable carrier, including water, emulsion, cream, ^Poor or a combination of them. And because the purpose of this group of money is to prevent = sunburn, the composition can be made into different forms, including sprays, ", lotion, pore cream or mask method, in order to facilitate the need for users to use the 'money frequency or dose can be adjusted according to the user's actual needs.,, mouth & the present invention to prevent skin sunburn The composition may optionally include makeup: an adjuvant or additive for hanging, such as an emulsifier, a tackifier, an interfacial active chelating agent, an antibacterial agent, a preservative, a coloring agent, a fragrance, etc. The professional knowledge, experience and needs of the company are selected from the appropriate substances and the amount of the additives is determined. Further, the composition for preventing sunburn of the present invention may further contain other active agents to provide additional skin. Benefits. Common active agents include, but are not limited to, Moisturizer II 9 200816926 Humectants, antioxidants, sunscreens, anti-aging agents, whitening, and emollients. Month Months and provide a free radical scavenging material and pharmaceutical composition. ^中=乐组成物 The extract of the black tea ammonia water of the present invention is used as an active ingredient: a medically acceptable excipient is mixed. The medically acceptable excipients include binding agents, fillers, and stabilizers. Further, the present invention also provides an anti-oxidation use and a doctor's advice. == The extract of the broad-band tea ammonia aqueous extract is used as an active ingredient; The medical agent includes a binder, a money filling, and a stabilizer. Then again! The invention also provides a use for inhibiting the growth of malignant tumors and a pharmaceutical active ingredient, which is mixed with a medically acceptable agent, and includes an excipient, a filler and a stabilizer. With scorpion cancer. The use of the basal cell, the basal cell, and the use of the present invention - a preferred embodiment of the present invention, the black tea ammonia of the present invention, can be transferred to the rectal cancer cells and the mobility of the needle Invasive ability. Silk cancer cells = tree _ real _, the hair of the "medicine composition system,", wood milk water draw is active age, (four) academically woven shirt w-shaped agent mixed 200816926, which is medically acceptable The excipient includes a binder, a filler and a stabilizer. Similarly, the pharmaceutical composition can be prepared into a drip, a syrup, a powder, a tablet, a capsule, a spray or a patch to facilitate the user's taking. However, the pharmaceutical composition of the present invention is not limited to the above several forms, and anyone skilled in the art can clearly understand that other modes of administration of the above composition are within the scope of the present invention. The pharmaceutical composition of the present invention can be based on those skilled in the art. The appropriate amount of the composition of the present invention can be used according to its own expertise, experience and needs. The frequency and dosage can be determined according to the severity of the symptoms, or according to the instructions or recommendations of a physician or the like. The present invention is specific but not limited The examples are described in more detail. Example 1: Preparation and identification of black tea ammonia water extract 1.1 Preparation of ammonia water extract The black tea leaves are boiled in hot water for 10 minutes, and boiled for cooking. The volume of the red tea leaves was soaked in 2% ammonia water at room temperature and stirred overnight at room temperature. The next day, the filtration was carried out, and the filtrate was treated under vacuum at a vacuum concentration machine at 50 ° C to make the total volume before concentration. 1/2. The obtained concentrate was titrated to ρΗ2·5 with 5N hydrochloric acid, and allowed to stand at room temperature for 4 hours, and then centrifuged at 10,000 g for 10 minutes, and the supernatant was removed to the -20 ° C refrigerator. Freeze. After thawing, remove the supernatant, dissolve the precipitate in 2% ammonia water before the acid titration, carry out the second extraction, and treat the remaining total volume at 5 CTC with a vacuum concentrator with a rotation speed of 90 rpm. 1/2 to 1/3. Acid titration to π 200816926 ρΗ2·5, and allowed to stand at room temperature for more than 4 hours, then transferred to a -20 ° C refrigerator to completely beaded. Remove the supernatant liquid. Add the 2% ammonia water in the volume before the second acid titration to dissolve it. Concentrate again, repeat the first and second extraction methods, and finally place the precipitate at _80 °C. Hours, in a freeze dryer (dura_DRY; FTS Systems, Inc. San Francisco, USA) Drying. The obtained dried product is the black tea ammonia water extract of the present invention. 1. 2 Electrospray ionization mass spectrometry (ESI-MS) The dried black tea ammonia water extract obtained in the foregoing Example 1.1 is electrically treated with other forms of extracts. A comparison of the analysis by spray free mass spectrometry, the extracted extracts include an aqueous extract prepared by a conventional method, an ethyl acetate extract and a 70% ethanol extract, wherein the aqueous ammonia extract and the aqueous extract are 1 Torr. The (mM) aqueous ammonia solution was redissolved into a solution of concentration μg/μl (μ§/μ1), while the other two extracts maintained the fluid state without further processing. The soil was continuously injected into the sample in a 250 μΐ syringe. The τ-type valve is used to connect the injection, and the pipeline of the pump and the LC pump is sent to the electric spray free source, and the current velocity of the above-mentioned soil is 20 μΐ/min (minutes). The average spectrum was obtained by completely scanning each of the first few minutes at a mass/charge ratio range of 150 to 25 Torr in the free state of the negative electrode. As shown in Figure 1 (8), the mass/charge ratios of the black tea ammonia extracts in the present invention are three specific values of lang, 226 3 and 368 6 respectively, and can be found in the mass spectrometric analysis of other black tea extracts. The mass/charge ratios of water extraction were (10)·8, 336.6 and _, respectively (the mass/charge ratios exhibited by the 12th 200816926 萃取 酉 酉 extract were 348 8 , 44 〇 6 and 883.0 respectively (Fig. i (10), and The ethanol extract is different from the side, the coffee and the rush ($1_. According to the mass spectrometry analysis above), it can effectively distinguish the water extract from the water, the acetic acid extract and the ethyl acetate. Unless otherwise specified, the black tea extract used in the following examples is the black tea ammonia water extract of the present invention prepared according to the present embodiment. Example 2: Ultraviolet absorption analysis of the black tea ammonia water extract of the present invention 2·ι mouse anti-UV test 8.1〇 weeks old retire cultivar (ICR) mice (purchased from the National Animal Center) After anesthesia with Avertin (15 ml/kg), the back hair was scraped off, as in the first 2 is divided into three areas, painted with water (area b), containing 丨% black tea extract A cream made from the method (area d) and a blank cream without extract (area c). Depending on the application dose (2 mg/cm2 and 2〇mg/cm2) and different UV wavelengths (UV) Light A (UV_A): 320 to 400 nm, UV_B: 290 to 320 nm, UV-C: 200 to 290 nm) The above-mentioned small gas is divided into 6 groups of at least 2 in each group, except for the part to be irradiated. The rest
均用遮蓋物覆蓋後,於UV-crosslinker ( Stratalinker出產) 中進行照射。UV-A照射時間為60分鐘(相當於144,〇〇〇焦 耳)’ IJV-B照射時間為30分鐘(相當於72,000焦耳)和UV-C 5照射時間為分鐘(相當於12,000焦耳),並持續觀察小鼠 變化。 13 200816926 四天後,將小鼠麻醉,頁下背部塗有不同樣品之皮声, 浸泡於10%中性福馬林中,並進行石蠟包埋、切片與^木 紫-伊紅(Hematoxylin & Eosin (HE))染色。 如第3圖所示,未經過任何處理(即第2圖中之區域 a)(第3圖⑻)或僅以水塗抹(第3圖(b))的小鼠皮膚在以 UV-B照射後,表皮細胞層明顯增加。而相較於未經^任何 處理或僅以水塗抹的小鼠皮膚,當以20mg(含1%紅茶氨水 萃取物之乳霜)/cm2(皮膚面積)的劑量塗抹小鼠皮膚能完全 抑制UV-B所引起的皮膚增生(第3圖(d)),而單獨以空白 乳霜塗抹皮膚時僅能部份抑制紫外線所引起的皮膚增生 (第3圖⑷)。 此外,如第4圖與第5圖所示,以本發明紅茶氨水萃 取物處理後的小鼠皮膚也能明顯阻擋1^^八或11\^(:所引起 的皮膚增生。因此上述結果顯示由本發明紅茶氨水萃取物 能有效保護皮膚不受到UV-A、UV-B與UV-C所引起的皮 膚傷害,而達到保護皮膚的功能。 2.2吸光值試驗 將紅茶萃取物溶於二次水成20 gg/mi的溶液後,利用 光譜儀(BECKMAN DU⑨640 spectrophotometer)以 200 至 600nm的波長範圍及1200 nm/min的掃描速率,測量本發 明紅茶氨水萃取物的吸光值,並記錄紫外光_可見光吸收光 譜0 14 200816926After being covered with a covering, it was irradiated in a UV-crosslinker (produced by Stratalinker). UV-A irradiation time is 60 minutes (equivalent to 144, 〇〇〇 joules) ' IJV-B irradiation time is 30 minutes (equivalent to 72,000 joules) and UV-C 5 irradiation time is minutes (equivalent to 12,000 joules), and Continue to observe changes in mice. 13 200816926 Four days later, the mice were anesthetized, and the lower back of the page was coated with different skin sounds, soaked in 10% neutral fumarin, and embedded in paraffin, sectioned with Hematoxylin & Eosin (HE)) staining. As shown in Fig. 3, the skin of the mouse without any treatment (ie, area a in Fig. 2) (Fig. 3 (8)) or only water (Fig. 3 (b)) is irradiated with UV-B. After that, the epidermal cell layer increased significantly. Compared to the skin of mice that have not been treated with any treatment or only with water, application of mouse skin at a dose of 20 mg (containing 1% black tea ammonia extract cream) / cm 2 (skin area) can completely inhibit UV Skin hyperplasia caused by -B (Fig. 3 (d)), and skin whitening alone can only partially inhibit skin hyperplasia caused by ultraviolet rays (Fig. 3 (4)). Further, as shown in Fig. 4 and Fig. 5, the skin of the mouse treated with the black tea ammonia aqueous extract of the present invention can also significantly block the skin hyperplasia caused by 1^^8 or 11 (^). The black tea ammonia water extract of the invention can effectively protect the skin from skin damage caused by UV-A, UV-B and UV-C, and achieve the function of protecting the skin. 2.2 Absorbance value test dissolves black tea extract into secondary water After 20 gg/mi solution, the absorbance of the black tea ammonia aqueous extract of the present invention was measured by a spectrometer (BECKMAN DU9640 spectrophotometer) at a wavelength range of 200 to 600 nm and a scan rate of 1200 nm/min, and the ultraviolet light-visible absorption spectrum was recorded. 0 14 200816926
如第6圖所示’本發明紅茶氨水萃取物的吸光值分布 在波長為200至400 nm的範圍,該範圍涵蓋了 υν·Α、uv_B 與UVC雜絲目,目此證實了树日妝魏水萃取物 能透過吸收紫外光來達到保護皮膚的功能。 2·3清除自由基試驗 - f斷1的0.05%本發明紅茶氨水萃取物溶液、5個 赢國P不單位(IU)的維生素E、01 mg/nil維生素C、2 mg/ml BHT •及0 05%合成黑色素(melanin)分別與4〇〇 μ1的〇 1M Tm-HC1 (ρΗ7·4)混合均勾,再加入5〇〇⑷的〇 $禮u_ 二苯基-2-苦基肼基(DPPH)混合’在室溫下靜置2〇分鐘, 再以517 nm的光學密度(OD)偵測。 本舍明紅茶氨水萃取物溶液與〇??^^試劑反應,結果 如第7圖所示’贿為雜_組,吸光值越滅表清除 ^由基能力越好。結果本發明紅茶氨水萃取物和已知具有 ^除自由基的m照’顯示本發明^茶氨水萃取物具有 清除自由基的能力’本發明紅茶氨水萃取物清除自由基的 功效較合成黑色素為佳。 2.4還原力試驗 將250 μ1的0.05%本發明紅茶氨水萃取物、5 kj維生 素Ε、0· 1 mg/mi維生素c和2 mg/ml ΒΗΤ分別與25〇 ^的 pH6.6 PBS 和 250 μΐ 的 1% K3Fe(CN)6 混合,置於 5〇t:水 /合槽20刀鐘。作用後移至冰上加入250 μΐ的tcA, 15 200816926 混合均勻’並以6,_啊離心1〇分鐘。取上清液45〇 μΐ 加上等體積的水與15〇μ1的〇.1%FeCl3_ ’室溫下靜置 5分鐘,以700 nm的光學密度債測。 還原力試驗的主要原理,是測定反應後普魯士藍(亞鐵 氰化鐵,以㈣卿]3)的產生量,作為還原力的高低指標。 結果如第8圖所示,紅茶氨水萃取物溶液、合成的黑色素 (melanin)和已知具有還原力的BHT、維生素e和維生素^ φ 相互對照,顯示本發明紅茶氨水萃取物和黑色素、BHT、 維生素E和維生素C 一樣有還原力的效果。' 實施例3 ·癌細胞生長與轉移的分析 3.1細胞培養與生長分析 本貝驗所使用的人類直腸癌細胞株Hct η 6與SW480 及子呂頸癌細胞株HeLa係購自於食品工業發展研究所生 物資源保存及研究中心(新竹,台灣),皮膚癌細胞株A431 • 及基皮細胞癌細胞株(BCC)(Jee et al·,0ncogene 20(2)· 198-208,2001)係由郭明亮博士(國立台灣大學醫學 - 院,毒理科)所提供。 所有的細胞株均以含10%胎牛血清(Bi〇west出產)的 DMEM (Dulbecco’s modified Eagle’s medium)培養基 (Biowest)培養於37。€含5%二氧化碳的組織培養箱。先將 細胞以5xl(^的密度種在六孔盤一天後,再進行假(m〇ek) 處理(未施以本發明紅茶氨水萃取物處理)或以不同濃度(25 16 200816926 gg/ml及125 pg/m〗)的本發明紅茶氨水萃取物處理細胞。經 過48小時後以椎藍質排出試驗(t響n — exdusi⑽議 利用血球計數器計算存活的細胞數。 如第9圖所示,直腸癌細胞株HCT116及sw4⑽在經過μ gg/ml及125 pg/ml的本發明紅茶氨水萃取物處理兩天後, ,、生長相較於假處理的細胞分別被抑制了 30-40%及 50_60/〇。此結果顯示本發明紅茶氨水萃取物在體外實驗可 ⑩ 依劑置顯著的抑制直腸癌細胞的生長。此外,本發明紅茶 氨水萃取物同樣也可以抑制子宮頸癌細胞株H e L a、皮膚癌 細胞株A431及基皮細胞癌細胞株的生長,證明本發明紅 余氨水萃取物對不同的癌細胞均具有抑制生長的效果。 3.2流數細胞儀分析 為探討細胞生長的減緩是否與增加的細胞死亡有關, 以冰冷的70%乙醇固定細胞3〇分鐘,接著用2〇〇从§/1111 ⑩ 的RNAse A (Pr〇mega出產)及5〇 yg/ml的碘化丙啶 二 (propiciium io㈣e)(Sigma出產)在37°C下處理細胞30分 . 鐘,再以流速細胞儀(BD Bi〇science出產)分析染色的細胞。 由於以凋亡蛋白酵素(caspase)路徑活化的内切酶切割 染色體DNA象徵了細胞凋亡,凋亡細胞的分解造成總DNA 量減少到比在細胞生長(G1)時期的細胞DNA量更低,結果 凋亡細胞的DNA贺在DNA量輪廓中里現低於生長時期細 胞DNA量的峰值。如第1〇圖所示,經25|^/1111本發明紅 茶氨水萃取物處理之直腸癌細胞株HCT116及SW48〇細胞 17 200816926 在次G1時期的細胞群分別佔44%與53%。相反的,在經 假處理的HCT116及SW480細胞只分別偵測到2%與5% 的-人G1 0^期細胞。這些結果顯示本發明紅茶氨水萃取物 能顯著造成直腸癌細胞的死亡。 3·3癌細胞移行试驗(migration assay) - 將癌細胞種在6孔盤並以補充ι〇%胎牛血清的 DMEM培養基培養直到癌細胞長滿(eonf|uence),利用消毒 馨 過的25Ό μΐ移液管尖刮破癌細胞單層以產生清理區域 zone),並在顯微鏡下觀察48小時内癌細胞移動到清理區 域的情況。在刮破癌細胞單層的同時及刮破後每六個小時 擷取影像,所測量的移行速率為移動距離(微米時間(小 時)。 如第11圖所示,經25 pg/ml本發明紅茶氨水萃取物處 理之直腸癌細胞株HCT116及SW480細胞較經假處理的 φ HCT116及SW480細胞分別降低了 53%及64%的移行速 • 率,而經125 gg/ml本發明紅茶氨水萃取物處理之HCT116 及SW480細胞則分別降低89%及94%的移行速率。因 此,以本發明紅茶氨水萃取物處理直腸癌細胞能顯著降低 直腸癌細胞的移行能力。 3·4人造基底層侵襲試驗(Matrigel invasion assay) 細胞侵襲試驗係在生物塗佈人造基底層侵襲槽 (BioCoat™ Matrigel™ Invasion Chamber)(Becton-Dickinson? 18 200816926As shown in Fig. 6, the absorbance value of the black tea ammonia water extract of the present invention is distributed in the range of wavelengths of 200 to 400 nm, and the range covers υν·Α, uv_B and UVC hybrids, thereby confirming the tree makeup Wei The water extract can absorb the ultraviolet light to protect the skin. 2. 3 scavenging free radical test - 0.05% of f broken 1 of the present invention, black tea ammonia aqueous extract solution, 5 wins of country P (IU) of vitamin E, 01 mg / nil of vitamin C, 2 mg / ml BHT • and 0 05% synthetic melanin (melanin) was mixed with 4〇〇μ1 of 〇1M Tm-HC1 (ρΗ7·4), and then added 5〇〇(4) of 礼$礼u_diphenyl-2-picrylhydryl (DPPH) Mixing was allowed to stand at room temperature for 2 minutes and then detected at an optical density (OD) of 517 nm. The Benximing black tea ammonia water extract solution reacts with the 〇??^^ reagent, and the result is as shown in Fig. 7, the bribe is a miscellaneous group, and the light absorption value is eliminated. RESULTS: The black tea ammonia water extract of the present invention and the m photo of the known free radicals show that the ammonia aqueous extract of the present invention has the ability to scavenge free radicals. The effect of the black tea ammonia water extract of the present invention on scavenging free radicals is better than that of synthetic melanin. . 2.4 Reducing power test 250 μl of 0.05% of the black tea ammonia extract of the present invention, 5 kj of vitamin Ε, 0·1 mg/mi of vitamin C and 2 mg/ml of hydrazine respectively with 25 〇 of pH 6.6 PBS and 250 μM 1% K3Fe(CN)6 mixed, placed in 5〇t: water/slot 20 knives. After the action, transfer to 250 μΐ of tcA on ice, 15 200816926 and mix evenly and centrifuge at 6, _ for 1 〇. The supernatant was taken at 45 〇 μΐ plus an equal volume of water and 15 μl of 〇.1% FeCl3_ ′ was allowed to stand at room temperature for 5 minutes, and measured at an optical density of 700 nm. The main principle of the reducing power test is to determine the amount of Prussian blue (ferric iron cyanide, (4) Qing] 3) after the reaction, as a high and low index of reducing power. As shown in Fig. 8, the black tea ammonia aqueous extract solution, the synthesized melanin and the known reducing power BHT, vitamin E and vitamin φ were compared with each other, and the black tea ammonia aqueous extract and the melanin, BHT, and the present invention were shown. Vitamin E has the same reducing power as vitamin C. Example 3 · Analysis of cancer cell growth and metastasis 3.1 Cell culture and growth analysis The human rectal cancer cell lines Hct η 6 and SW480 used in the laboratory and the HeLa line of the cervical cancer cell line were purchased from the food industry development research. The Center for Biological Resource Conservation and Research (Hsinchu, Taiwan), the skin cancer cell line A431 • and the basal cell carcinoma cell line (BCC) (Jee et al., 0ncogene 20(2)· 198-208, 2001) by Guo Dr. Bright (National Taiwan University Medicine - Hospital, Department of Toxicology). All cell lines were cultured at 37 in DMEM (Dulbecco's modified Eagle's medium) medium (Biowest) containing 10% fetal bovine serum (produced by Bi〇west). € Tissue incubator with 5% carbon dioxide. First, the cells were seeded at a density of 5×l (a density of 1 day in a six-well plate, followed by a false (m〇ek) treatment (not treated with the black tea ammonia aqueous extract of the present invention) or at different concentrations (25 16 200816926 gg/ml and The cells were treated with the black tea ammonia aqueous extract of the present invention at 125 pg/m. After 48 hours, the vertebral blue discharge test was performed (t ring n-exdusi (10). The number of viable cells was counted using a hemocytometer. As shown in Fig. 9, the rectum The cancer cell lines HCT116 and sw4(10) were inhibited by 30-40% and 50_60/, respectively, after being treated with μ gg/ml and 125 pg/ml of the black tea ammonia aqueous extract of the present invention for two days.结果. The results show that the black tea ammonia water extract of the present invention can significantly inhibit the growth of rectal cancer cells in vitro. In addition, the black tea ammonia water extract of the present invention can also inhibit the cervical cancer cell line He e L a , The growth of the skin cancer cell line A431 and the basal cell carcinoma cell line proves that the red residual ammonia water extract of the present invention has the effect of inhibiting growth of different cancer cells. 3.2 Flow number cytometry analysis to investigate whether the cell growth slowdown is increased or not Related to cell death, cells were fixed in ice-cold 70% ethanol for 3 min, followed by 2 〇〇 from §/1111 10 RNAse A (Pr〇mega produced) and 5 〇yg/ml propidium iodide (propiciium) Io (d) e) (produced by Sigma) The cells were treated at 37 ° C for 30 minutes, and the stained cells were analyzed by flow cytometry (BD Bi〇science). Endonucleases activated by the caspase pathway Cleavage of chromosomal DNA symbolizes apoptosis, and the breakdown of apoptotic cells causes the total amount of DNA to decrease to a lower amount than that of cells during the cell growth (G1) period. As a result, the DNA of apoptotic cells is lower than the DNA profile. The peak amount of cellular DNA during the growth period. As shown in Fig. 1, the rectal cancer cell lines HCT116 and SW48〇 cells treated with 25|^/1111 of the black tea ammonia aqueous extract of the present invention 17 200816926 accounted for the cell population in the sub G1 period, respectively. 44% and 53%. Conversely, only 2% and 5% of human G1 0 phase cells were detected in the pseudo-treated HCT116 and SW480 cells. These results show that the black tea ammonia extract of the present invention can significantly cause the rectum Cancer cell death. 3. 3 cancer cell migration test ( Migration assay) - The cancer cells are seeded in 6-well plates and cultured in DMEM medium supplemented with 〇% fetal bovine serum until the cancer cells are overgrown (eonf|uence), and the cancer is scraped with a sterile 25 μm pipette tip. The cell monolayer was used to create a cleaned zone, and the cells were moved to the cleaned area within 48 hours under a microscope. The image was taken every six hours while scratching the monolayer of the cancer cell and after the scraping, and the measured migration rate was the moving distance (micron time (hours). As shown in Fig. 11, the invention was 25 pg/ml The rectal cancer cell lines HCT116 and SW480 cells treated with black tea ammonia extract reduced the migration rate by 53% and 64%, respectively, compared with the pseudo-treated φ HCT116 and SW480 cells, and the 125 mg/ml black tea ammonia water extract of the present invention. The treated HCT116 and SW480 cells reduced the migration rate by 89% and 94%, respectively. Therefore, treatment of rectal cancer cells with the black tea ammonia aqueous extract of the present invention can significantly reduce the migration ability of rectal cancer cells. 3.4 Artificial basal layer invasion test ( Matrigel invasion assay) The cell invasion assay is in the BioCoatTM MatrigelTM Invasion Chamber (Becton-Dickinson? 18 200816926)
Bedford, ΜΑ)中根據廠商所提供的步驟進行分析。在每_ 槽内加入於500μ1 DMEM培養基中的細胞(2xl〇5),並置於 37°C含5%二氧化碳的組織培養箱中任其侵襲人造基底層 48小時。去除在槽膜上表面的非侵襲細胞,並將在槽膜下 表面的侵襲細胞以100%甲醇固定,接著以〇·5%的結晶 紫(crystal violet)溶液(Sigma)進行細胞染色。以蒸餾水清洗 兩次後,將槽風乾。在相差顯微鏡下計算視野中之侵襲細 胞數目,並計算顯微鏡下5個不同視野中細胞數的平均值土 標準差。 如第12圖所示,以25 Hg/ml的本發明紅茶氨水萃取物 處理直腸癌細胞株HCT116及SW480細胞後,具侵襲能力 的細胞數分別減少了 85%及97% ,而以125 pg/mi的本 發明紅茶氨水萃取物處理HCT116及SW480細胞則分別減 少了 97%及99%具侵襲能力的細胞數。這些結果顯示本 發明紅茶氨水萃取物也能有效阻止癌細胞的侵襲。 【圖式簡單說明】 第1圖為利用電喷灑游離質譜分析不同紅茶萃取物的 貝增圖。(a)為本發明之紅茶氨水萃取物;(b)為水萃取物; (c)為醋酸乙酯萃取物;(d)為乙醇萃取物。 第2圖係一宏觀圖像(macr〇sc〇pic jmage)顯示一隻遠 父品種(ICR)小鼠背部剃除毛髮後的皮膚,該塊皮膚上更標 有a、b、c、d四個不同處理區域。 19 200816926 第3圖顯示在遠交品種小鼠背部皮产a 再以IJV-B照射後所取得的皮膚組織切胃^以不同處理後 倍的放大倍率。(a)為未經過任何處理之唐固像具有400 之皮膚;(e)為塗抹空白乳霜之皮膚;^ (b)為塗抹水 氨水萃取物乳霜之皮膚。 馬塗抹含1%紅茶 第4圖顯示在遠交品種小鼠背部 再以UVC照射所取得的皮膚組織切片,談::不同處理後 的放大倍率。⑻為未經過任何處理之皮_倍 皮膚;⑻為塗抹空白乳霜之皮膚;抹水之 水萃取物乳霜之皮膚。 ’、’、塗抹3 1%紅茶氨 第5圖顯示在遠交品 的放大倍率。皮/切片’該圖像具有倍 皮膚。 )為未、‘過任何處理之皮膚;⑻為塗抹水之 得到光光譜儀分析本發明紅茶氨水萃取物所 樣本 清除茶氨水萃取物與其他已知 第 之還原力本發明紅茶氨水萃取物與其他已知樣本 長 的條=圖料析本發料純水萃取物抑制癌細胞生 20 200816926 第ίο圖顯示以流速細胞儀分析本發明紅茶氨水萃取 物造成直腸癌細胞死亡的影響。 第11圖係分析本發明紅茶氨水萃取物抑制直腸癌細 胞之移行能力的條狀圖。 第12圖係分析本發明紅茶氨水萃取物抑制直腸癌細 胞之侵襲能力的條狀圖。Bedford, ΜΑ) is analyzed according to the steps provided by the manufacturer. The cells (2xl〇5) in 500 μl of DMEM medium were added to each well and placed in a tissue culture incubator containing 5% carbon dioxide at 37 ° C for any time to invade the artificial basal layer for 48 hours. The non-invasive cells on the upper surface of the trough membrane were removed, and the invading cells on the lower surface of the trough membrane were fixed with 100% methanol, followed by cell staining with 〇·5% crystal violet solution (Sigma). After washing twice with distilled water, the tank was air dried. The number of invading cells in the visual field was calculated under a phase contrast microscope, and the mean standard deviation of the number of cells in five different fields of view under the microscope was calculated. As shown in Fig. 12, after treatment of rectal cancer cell lines HCT116 and SW480 cells with 25 Hg/ml of the black tea ammonia aqueous extract of the present invention, the number of invasive cells was reduced by 85% and 97%, respectively, and 125 pg/ The treatment of HCT116 and SW480 cells by the ammonia aqueous extract of the present invention of mi of the present invention reduced the number of invasive cells by 97% and 99%, respectively. These results show that the black tea ammonia aqueous extract of the present invention can also effectively prevent the invasion of cancer cells. [Simple description of the diagram] Figure 1 is a graph of the analysis of different black tea extracts by electrospray ionization mass spectrometry. (a) is an extract of black tea ammonia water of the present invention; (b) is an aqueous extract; (c) is an ethyl acetate extract; and (d) is an ethanol extract. Figure 2 is a macro image (macr〇sc〇pic jmage) showing the skin of a far-parent breed (ICR) mouse after shaving the hair. The skin is marked with a, b, c, d. Different processing areas. 19 200816926 Fig. 3 shows the magnification of the skin tissue cut in the back skin of the outbred mice and then treated with IJV-B. (a) 400 skins without any treatment; (e) skin with a blank cream; (b) skin with a water-ammonia extract cream. Horse smear containing 1% black tea Figure 4 shows the skin tissue sections obtained by UVC irradiation on the back of the overcrossed mice. Talk about: Magnification after different treatments. (8) Skin that has not been treated to _ times skin; (8) Skin that is applied with a blank cream; Water of the water-washing cream. ',', smear 3 1% black tea ammonia Figure 5 shows the magnification of the far-off product. Skin/Slice 'This image has double skin. (8) For the skin that has not been treated, (8) For the analysis of the black water ammonia extract of the present invention, the sample of the black tea ammonia water extract of the present invention is used to remove the tea ammonia water extract and other known reducing powers. The black tea ammonia water extract of the present invention and others have been Knowing the length of the sample = the data of the present invention, the pure water extract inhibits the growth of cancer cells 20 200816926 The figure shows the effect of analyzing the black tea ammonia aqueous extract of the present invention on the death of rectal cancer cells by flow rate cytometry. Fig. 11 is a bar graph for analyzing the ability of the aqueous extract of black tea of the present invention to inhibit the migration of rectal cancer cells. Fig. 12 is a bar graph for analyzing the invasive ability of the black tea ammonia aqueous extract of the present invention to inhibit rectal cancer cells.
21twenty one
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW95136486A TW200816926A (en) | 2006-10-02 | 2006-10-02 | A black tea extract and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW95136486A TW200816926A (en) | 2006-10-02 | 2006-10-02 | A black tea extract and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200816926A true TW200816926A (en) | 2008-04-16 |
Family
ID=44769230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW95136486A TW200816926A (en) | 2006-10-02 | 2006-10-02 | A black tea extract and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TW200816926A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11752183B2 (en) | 2017-04-03 | 2023-09-12 | Tci Co., Ltd | Compositions of plant extracts for reducing UV damage |
-
2006
- 2006-10-02 TW TW95136486A patent/TW200816926A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11752183B2 (en) | 2017-04-03 | 2023-09-12 | Tci Co., Ltd | Compositions of plant extracts for reducing UV damage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105030622B (en) | A kind of lightening compositions and preparation method thereof | |
| CN111228200A (en) | Whitening composition, whitening essence containing whitening composition and preparation method thereof | |
| TW201031433A (en) | Skin-whitening agent, anti-aging agent, and anti-oxidant agent | |
| CN115590795A (en) | Cosmetic composition for skin elasticity enhancement or wrinkle improvement comprising Polygonum cuspidatum root extract | |
| TW201700108A (en) | Phalaenopsis extract for whitening skin and resisting skin aging capable of reducing the activity of tyrosinase and being anti-oxidative , capable of whitening the skin and slowing down the phenomenon of skin aging | |
| CN101181209A (en) | The application of the red tassel chrysanthemum in the inhibition of tyrosinase and anti-ultraviolet | |
| CN107320363A (en) | A kind of anti-acne essence | |
| CN1984637A (en) | Skin aging treatment comprising paeoniflorin | |
| JPH04346911A (en) | Cosmetic | |
| JP5770428B2 (en) | Singlet oxygen scavenger, skin external preparation and cosmetic using the singlet oxygen scavenger | |
| KR20100010647A (en) | Patch for inhibiting hair loss and enhancing hair growth | |
| US20100166683A1 (en) | Composition of external preparation for uv-protection comprising rehmannia glutinosa extracts | |
| JPH0812560A (en) | Skin external preparation | |
| JP2003183175A (en) | alpha-MSH INHIBITOR ORIGINATING FROM TEA EXTRACT AND WHITENING AGENT, ANTI-AGING AGENT AND MMP-1 PRODUCTION INHIBITOR CONTAINING THE SAME, AND SKIN CARE PREPARATION CONTAINING THESE | |
| KR101214347B1 (en) | Method for Extracting Herbal Ingredient | |
| JP2002173441A (en) | Antioxidant or preventive agent for living body | |
| TW200816926A (en) | A black tea extract and uses thereof | |
| JPH0812561A (en) | Beautifying and whitening skin preparation for external use | |
| JP2011168543A (en) | Singlet oxygen scavenger, and skin care external preparation and cosmetic each using the singlet oxygen scavenger | |
| KR102228086B1 (en) | Hair coloring composition having antimicrobial and deodorizing activity and ammonia odor removal effet | |
| KR102162904B1 (en) | Hair coloring composition and the manufacturing process having antimicrobial and antiflammatory and deodorizing activity and ammonia odor removal effet | |
| KR20010038100A (en) | Cosmetic compositions for skin whitening containing extract of galenical medicines | |
| CN101161267A (en) | Black tea extract and application thereof | |
| JP3452671B2 (en) | External preparation for skin | |
| KR101957411B1 (en) | Cosmetic composition for improving skin conditions comprising herbal extracts-containing pectin microcapsule |